-
A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study
Powles, T., Valderrama, B. P., Gupta, S., Bedke, J., Kikuchi, E., Hoffman-Censits, J., Iyer, G., Vulsteke, C., Park, S. H., Shin, S. J., Castellano, D., Fornarini, G., Li, J.-R., Gümüş, M., Mar, N., Loriot, Y., Fléchon, A., Duran, I., Drakaki, A. & Narayanan, S. & 4 others, , 2025, In: Future Oncology. 21, 7, p. 749-764 16 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial
Powles, T. B., van der Heijden, M. S., Loriot, Y., Bedke, J., Valderrama, B. P., Iyer, G., Kikuchi, E., Hoffman-Censits, J., Vulsteke, C., Drakaki, A., Rausch, S., Arafat, W., Park, S. H., Swami, U., Li, J. R., Duran, I., Gorla, S., Homet Moreno, B., Yu, X. & Lu, Y. T. & 1 others, , 2025, (E-pub ahead of print) In: Annals of Oncology.Research output: Contribution to journal › Article* › Academic › peer-review
-
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
Rosenberg, J. E., Galsky, M. D., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., van der Heijden, M. S., Dreicer, R., Durán, I., Castellano, D., Drakaki, A., Retz, M., Sridhar, S. S., Grivas, P., Yu, E. Y., O'Donnell, P. H. & Burris, H. A. & 4 others, , 1 Dec 2024, In: ESMO open. 9, 12, 103972.Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
